Website is under construction and will be updated soon
Building a robust oncology portfolio to address significant unmet needs via the targeting of CSF1R:
- Minimal residual disease (MRD) in Colorectal Cancer that will progress to metastasis if left untreated
- Tenosynovial giant cell tumor (TGCT), a locally aggressive joint sarcoma, that can benefit from a novel local administration, to expand physician treatment options
- Acute Myeloid Leukemia (AML) via an antibody drug conjugate (ADC) format
R&D pipeline – leveraging clinically-validated CSF1R MOA in highly differentiated oncology programs with large commercial opportunities
TAM* = Total Addressable Market in the US and EU
Latest news
Sep 27, 2024
AmMax Bio to Present at the Oppenheimer Healthcare Private Company Showcase
Corp Dev & Partnering
Laura Zhu, Ph.D., MBA
Chief Business Officer
- 1 (650) 285-6560 ext. 103
- laurazhu@ammaxbio.com
Larry Hsu, PhD
Chief Executive Officer
- 1 (650) 285-6560
- larryhsu@ammaxbio.com
©2024 AmMax Bio Inc.